SCHEDULE: Janus Henderson Discloses 9.99% Stake in INOVIO

Janus Henderson Group plc has reported a 9.99% beneficial ownership stake in INOVIO Pharmaceuticals, Inc., primarily through shared voting and dispositive power.

Summary

• Janus Henderson Group plc, a Jersey-based entity, has filed a Schedule 13G indicating beneficial ownership of 6,666,295 shares of INOVIO Pharmaceuticals, Inc. common stock.
• This ownership represents 9.99% of INOVIO's outstanding common stock.
• Janus Henderson Group plc holds shared voting power and shared dispositive power over all 6,666,295 shares, with no sole voting or dispositive power.
• The reported shares are inclusive of certain pre-funded and/or common warrants.
• An additional 991,856 Series A and 991,856 Series B common warrants are not reflected in the reported figures due to a beneficial ownership limitation, which restricts exercise if it would result in ownership exceeding 9.99% of the outstanding common stock.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of INOVIO Pharmaceuticals, Inc.

Sentiment

Score: 7

Explanation: The filing indicates a significant institutional investment in INOVIO Pharmaceuticals by Janus Henderson, suggesting confidence in the company's prospects, albeit as a passive stake. This is generally viewed positively by the market.

Positives

• A significant institutional investor, Janus Henderson Group plc, has taken a substantial 9.99% stake in INOVIO Pharmaceuticals, Inc., which can be viewed as a vote of confidence in the company's long-term prospects.
• The investment is stated to be for ordinary course of business, indicating a passive, long-term investment rather than an activist stance.

Risks

• The beneficial ownership includes warrants that are subject to a 9.99% ownership limitation, meaning additional warrants (991,856 Series A and 991,856 Series B) are not currently exercisable or reflected in the reported ownership due to this cap, potentially limiting immediate upside from these instruments.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding INOVIO Pharmaceuticals, Inc.'s financial performance or operational outlook, nor does it detail Janus Henderson's future investment strategy beyond the passive nature of the current stake.

Management Comments

• Janus Henderson Group plc certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose or with the effect of changing or influencing the control of INOVIO Pharmaceuticals, Inc.

Industry Context

This filing represents a standard disclosure of a significant passive institutional investment in a publicly traded company within the biotechnology sector. Janus Henderson Group plc is a global asset manager, and its investment in INOVIO Pharmaceuticals, Inc. reflects a portfolio allocation decision rather than a strategic industry move.

Stakeholder Impact

• Shareholders of INOVIO Pharmaceuticals, Inc. may view the significant institutional stake by Janus Henderson Group plc as a positive signal of investor confidence and potential stability in the stock.

Key Dates

Recommendation

Janus Henderson Group plc's disclosure of a 9.99% beneficial ownership in INOVIO Pharmaceuticals, Inc. indicates significant institutional interest. While this is a passive investment and does not signal an intent to influence control, the substantial stake from a reputable asset manager could be viewed positively by the market. However, without further financial or operational updates from INOVIO, a 'hold' recommendation is appropriate to observe future developments.

Keywords

INOVIO Pharmaceuticals, Janus Henderson, Schedule 13G, beneficial ownership, common stock, institutional investment, warrants, passive stake